Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fatty acid oxidation pathway enzymes refer collectively to a group of mitochondrial and peroxisomal **enzymes responsible for breaking down fatty acids into acetyl-CoA**, which is then used in the citric acid cycle to generate ATP. The canonical process is called **beta oxidation**. The main mitochondrial beta oxidation enzymes are: 1. **Acyl-CoA dehydrogenases** – catalyze initial dehydrogenation; exist as isoforms with specificity for very-long-, long-, medium-, or short-chain acyl groups. 2. **Enoyl-CoA hydratase** – hydrates the double bond formed by acyl-CoA dehydrogenases. 3. **Hydroxyacyl-CoA dehydrogenase** – oxidizes hydroxyl groups on beta carbon. 4. **Ketoacyl-CoA thiolase** – cleaves two-carbon units as acetyl CoA. Additional steps include activation by acyl CoA synthetases and transport via carnitine shuttle proteins such as CPT1/CPT2. Deficiencies in these enzymes lead to metabolic diseases such as MCAD deficiency and Refsum disease[2][3]. These pathways are essential for energy homeostasis during fasting or exercise when glucose is scarce. The entry "Fatty acid oxidation pathway enzymes" is not a single molecular target but rather a functional class comprising multiple distinct proteins/enzymes that each could be considered an individual therapeutic target[1][5]. For structured data purposes it should be split into its constituent canonical forms—such as "Medium-chain acyl-Coenzyme A dehydrogenase"—rather than treated as one entity. > “This process involves a variety of enzymes...with different affinities for different fatty acid chain lengths...the enoyl‐CoA hydratase, hydroxyacyl‐CoA dehydrogenase and ketoacly‐Coa isoforms specific for long chain fatty acids form an enzyme complex on the inner mitochondrial membrane.” [1] > “The first [enzyme] is acycl‐Coa Dehyderogenese...comes in three different forms–ones that work on long medium or short chain length fatty acids.” [2] > “Defects in these pathways…such as MCAD deficiency…as well as impact of dysregulated lipoprotein metabolism on cardiovascular risk.” [3]
Inhibition of specific enzymes in the pathway can reduce fatty acid oxidation and energy production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fatty acid oxidation pathway enzyme.